Associations of circulating microRNAs (miR-17, miR-21, and miR-150) and chronic kidney disease in a Japanese population

Ryosuke Fujii¹, Hiroya Yamada², Eiji Munetsuna³, Mirai Yamazaki⁴, Koji Ohashi⁴, Hiroaki Ishikawa⁴, Keisuke Maeda¹, Chiharu Hagiwara¹, Yoshihata Ando⁴, Shuji Hashimoto², Nobuyuki Hamajima³, Koji Suzuki¹*

¹ Department of Preventive Medical Sciences, Fujita Health University School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192 Japan

² Department of Hygiene, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192 Japan

³ Department of Biochemistry, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192 Japan

⁴ Department of Clinical Biochemistry, Fujita Health University School of Health Sciences, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192 Japan

⁵ Department of Healthcare Administration, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550 Japan

Address for correspondence
*Corresponding author: Koji Suzuki, Ph.D.

E-mail: ksuzuki@fujita-hu.ac.jp

Address: 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192 Japan

Tel: +81 562 93 2537

Fax: +81 562 93 4595

**Running Title:** Circulating microRNAs and chronic kidney disease

**Tables and Figures:** Tables 4, Figure 1
Abstract

Background: MicroRNAs (miRNAs) play crucial roles in the development of various diseases, including chronic kidney disease (CKD). Although previous studies in clinically severe patients have investigated associations between CKD and miRNAs with particular attention on renal fibrosis, relationships in a general population have yet to be established. The aim of this study was to examine the relationship between expression level of circulating miRNAs and CKD in a middle-aged Japanese population.

Methods: A final total of 513 individuals (216 men, 297 women) who participated in the health check-up program in 2012 were included in our analysis. The quantitative real-time polymerase chain reaction was used to determine expression levels of 22 miRNAs. Estimated glomerular filtration rate (eGFR) was calculated based on serum creatinine level, sex, and age. Participants with eGFR < 60 mL/min/1.73 m² were defined as having CKD.

Results: Three different miRNAs (miR-17, miR-21, and miR-150) showed significant correlations with eGFR after Bonferroni correction and were selected for further analyses. Expression levels of three miRNAs were positively associated with eGFR after adjusting for potential confounders ($p = 0.004, 0.002, \text{ and } 0.004$, respectively). Logistic regression analyses showed significantly lower odds ratios for CKD (eGFR < 60 mL/min/1.73 m²) in the highest tertile of all three miRNAs (miR-17, miR-21, and miR-150) compared with the lowest tertile ($p = 0.003, 0.01, \text{ and } 0.02$, respectively).
Conclusions: We found three circulating miRNAs were significantly associated with CKD in a general Japanese population, which suggested that these miRNAs may be a biomarker for CKD among general adults.

Keywords: chronic kidney disease, microRNA, cross-sectional study, molecular epidemiology, epigenetics
Introduction

MicroRNAs (miRNAs) are small non-coding RNAs with a length of 18-25 nucleotides, and regulate gene expression by binding to the 3'-untranslated region of the target mRNA. With advances in molecular biology and technology, miRNAs have been a focus of recent medical research. Approximately 3,000 species of human miRNAs have been identified to date and regulate over 30% of all human transcripts. Accumulated evidence has revealed that miRNAs are associated with various pathophysiological conditions and the development of diseases such as cancer, cardiovascular disease (CVD), diabetes, liver disease, kidney disease, and autoimmune disease. In addition, previous studies have demonstrated that miRNAs are highly stable in body fluids such as serum and urine, because protein-bound or microvesicle-derived miRNAs in blood vessels are protected from degradation. Taken together, circulating miRNAs represent candidate biomarkers to diagnose and monitor disease.

Patients with chronic kidney disease (CKD) has become one of the health concerns in Japan, as well as in developed countries around the world. The number of individuals with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², the cut-off value of CKD widely used in clinical settings, in Japan has reached approximately 13 million, equal to about 13% of the Japanese adult population. The development and progress of CKD relies on the combination of pathophysiological conditions including chronic inflammation.
and increased cell stress, and results in renal fibrosis in the final pathological stage of CKD.

Interestingly, chronic inflammation is associated with epigenetic modifications, such as DNA methylation and RNA interference (by miRNAs), via inflammation mediators. Capturing alterations of these molecules is thus important for preventing from the progression of CKD.

Numerous studies have investigated the associations of CKD and miRNAs in clinically severe patients and experimental animals, with particular attention to renal fibrosis. The majority of previous studies have thus focused on and analyzed expression levels of tissue-specific miRNAs in the kidneys. Abundant evidence on the association of miRNAs and renal fibrosis has suggested that miR-21 is strongly linked to renal pathogenesis, particularly renal fibrosis. However, whether this relationship is applicable to mildly impaired patients or the general population without renal fibrosis remains to be determined. The present study therefore investigated the relationships between expression levels of 22 circulating miRNAs and renal function in a middle-aged Japanese population.

Subjects and Methods

Study subjects

A community-based health examination has been conducted in Yakumo town, Hokkaido, in the northern part of Japan, at the end of August every year. Information of this health
examination is provided for every household by a public relations magazine in advance. The volunteers aged 39 or older at the health-examination and residing in Yakumo Town are eligible to this health examination. Those who do not accept to participate in this study or those who cannot complete the lifestyle questionnaire are excluded from subjects for the research. This cross-sectional study is part of the Yakumo study, a population-based prospective study conducted in this area. A total of 556 eligible residents participated in the health examination in August 2012. Among all those participants, 33 individuals who declined to participate in this research were excluded. Two individuals were excluded due to incomplete questionnaires. Eight women who did not undergo the rapid urine test were also excluded, thereby yielding a total sample of 513 residents (216 men, 297 women) for our analysis. Written informed consent was obtained from all participants of this study.

The protocol of this study was approved by the Ethics Review Committee of Fujita Health University (Approval No. 164).

**Data collection**

We collected a broad range of participants’ information, including blood laboratory data, lifestyle information, cognitive function test, and ultrasound examination, during the health examination. A self-administered questionnaire regarding lifestyle information was distributed to applicants prior to the health examination. Municipal public health nurses
collected and checked for missing data with interviews at the health examination site. The following four lifestyle-related variables were defined as shown below: 1) smoking status (current, ever, or never); 2) alcohol consumption (current, ever, or never); 3) exercise habit (almost none, 1-2 h/week, 3-4 h/week, or ≥ 5 h/week); and 4) current medications for at least one of the four diseases of heart disease, diabetes mellitus, hypertension, or dyslipidemia (yes or no). During the health examination, urine and fasting serum samples were collected from each participant. The rapid urine test was performed to evaluate substances in urine, including protein, glucose, and erythrocytes. Collected blood samples were centrifuged within an hour of sampling and stored at −80°C until measurement. Quality-controlled biochemical analyses were performed using autoanalyzers in the laboratory of Yakumo Town Hospital. We calculated eGFR according to the equation proposed by the Japanese Society of Nephrology: eGFR = 194 × serum creatinine$^{-1.094}$ × age$^{-0.287}$ (× 0.739 for women). According to the clinical guideline in Japan, we regarded individuals with eGFR < 60 mL/min/1.73 m² (CKD stage 3–5) as CKD in this study.

Measurement of microRNAs

Quantitative real-time polymerase chain reaction (qPCR) was used to detect expression levels of 22 miRNAs in sera; details of this procedure have been described elsewhere. Based on the previous studies, we selected these 22 miRNAs associated with metabolic
phenotypes and diseases, prior to the health examination in 2012.\textsuperscript{10,40,41} Relative expressions of each miRNA were calculated using the comparative cycle threshold (CT) method ($2^{\Delta \Delta CT}$). We used synthesize \textit{C. elegans} miR-39 (cel-mir-39) levels as an external validation to check either the extraction of RNA or the efficacy of the cDNA synthesis.\textsuperscript{42,43}

In this study, we used cel-miR-39 as a spike-in control in the measurement of circulating miRNAs. Although this method has several drawbacks,\textsuperscript{44,45} few miRNAs have been identified as an internal control in recent studies. Therefore, our method is a widely used and ideal method in the measurement of circulating miRNAs.\textsuperscript{46–49} 20–30 different individuals failed in the measurement of each miRNA and were excluded in our analysis. Therefore, the number of subjects included in statistical analysis differed by miRNAs.

\textit{Statistical analysis}

Normally distributed continuous variables are represented as mean and standard deviation (SD), while triglycerides (TGs) are expressed as the median (1\textsuperscript{st} and 3\textsuperscript{rd} quartile) because of the non-Gaussian distribution. The expression level of circulating miRNAs was logarithmically transformed into a normal distribution in our analyses. Pearson correlation coefficients were calculated to examine linear relationships between 22 miRNAs and eGFR. The level of significance was defined as a value of $p < 0.05$ divided by the number of comparisons based on the Bonferroni correction ($2.27 \times 10^{-3}$). Those miRNAs passing
the threshold for significance were selected as plausible candidates for consecutive regression analysis. We used multiple linear regression analysis to examine the association between miRNA and eGFR. In order to estimate risk of CKD in different expression levels of miRNAs, we split participants equally into three groups “tertiles” (low, middle, and high) according to the expression level of each miRNA. Multivariable logistic regression analysis was performed to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the presence of renal dysfunction (eGFR < 60 mL/min/1.73 m²) using the lowest tertile as a reference group. These analyses were performed after adjustment for sex, age, proteinuria, body mass index, TG, systolic blood pressure, blood glucose, smoking status, alcohol consumption status, exercise habit, and medication for non-communicable diseases. These potential confounding factors were selected based on the previous study conducted in Japan. Values of \( p < 0.05 \) were considered statistically significant, and all tests were two-tailed. Statistical analyses were performed using R version 3.5.0 statistical software.

**Results**

Basic characteristics of participants stratified by CKD status are shown in Table 1. Mean ages (years) of participants were 65.6 (9.5) in men and 63.3 (9.4) in women. Significant differences between normal kidney function (n = 395) and those who had CKD (n = 118) were observed only in age and medications for metabolic syndrome (both \( p < 0.001 \).
Correlations between 22 miRNAs and eGFR

Pearson correlation coefficients between miRNAs and eGFR are summarized in Table 2. Three different miRNAs (miR-17, miR-21, and miR-150) correlated significantly with eGFR after Bonferroni correction and were selected for regression analyses. Figure 1 shows positive correlations between the log-transformed values of three miRNAs and eGFR.

Multivariable linear regression between three miRNAs and eGFR

In the multivariable linear regression analyses, selected miRNAs (miR-17, miR-21, and miR-150) were positively associated with eGFR, with standardized $\beta$ values of 0.121, 0.134, and 0.123 ($p = 0.004$, 0.002, and 0.004, respectively), indicating that expression levels of these miRNAs were greater with normal kidney function (Table 3).

Odds ratio for risk of renal dysfunction

Table 4 shows adjusted ORs with 95% CIs for risk of renal dysfunction according to miRNA level. Logistic regression modeling indicates that the highest tertile in three miRNAs had significantly lower ORs of renal dysfunction compared with the lowest tertile. We also confirmed the significant linear trends of ORs for renal dysfunction according to
tertiles of the three miRNAs (miR-17, miR-21, and miR-150) \( p = 0.003, 0.01, \) and 0.02, respectively).

Discussion

This study examined the association between circulating miRNAs and eGFR-based renal function in a middle-aged Japanese population. We found that expression levels of three different miRNAs (miR-17, miR-21, and miR-150) were significantly associated with eGFR after adjusting for potential confounders. Furthermore, the highest expression group in three miRNAs had a lower OR for renal dysfunction compared with the lowest expression group.

Previous studies have suggested that miR-21 may play a profibrotic role in the field of nephrology.\(^{26-35,51-53}\) Glowacki et al. found a strong upregulation of miR-21 levels in the kidneys of mice with unilateral ureteral obstruction (UUO) and patients with severe kidney fibrosis.\(^{26}\) Other previous studies observed increased miR-21 levels was associated with renal fibrosis in animal models or in patient groups.\(^{28,33,34}\) Although previous studies largely focused on tissue miR-21 expression and fibrosis and have been conducted in patients, they did not examined the association of circulating miR-21 level and renal function among healthy adults. Therefore, we tested the hypothesis that circulating miR-21 levels are associated with renal function. Contrary to our expectation, the results showed
that circulating miR-21 level was positively associated with kidney function. This result was accordance with only a study regarding to the associations between miRNAs and renal function. Even though few previous studies have been reported in the field of nephrology, one possible reason for this discrepancy between our results and previous studies is that the anti-inflammatory properties of miR-21 could play a protective role in the kidney. Previous studies have shown that up-regulation of miR-21 silenced phosphatase and tensin homolog deleted on chromosome10 (PTEN) and programmed cell death protein 4 (PDCD4) as targeted genes. Inhibition of these tumor suppressor genes resulted in decreased levels of nuclear factor-kappa beta (NF-κβ), tumor necrosis factor alpha (TNF-α), and interleukin 6 (IL-6), and increased levels of IL-10, which eventually accounts for an anti-inflammatory function of miR-21. Considering these evidences in molecular biology, a conceivable mechanism underlying our results could be that higher miR-21 expression level induced lower inflammatory cytokines through targeting PTEN and PDCD4, and consequently linked to lower inflammation and normal kidney function. Future works should thus focus on the relationship between expression level of circulating miR-21 and other inflammatory cytokines, which could get to the heart of this association between miR-21 and CKD in a population with normal kidney function. Another speculations for the decreased miR-21 levels in CKD was that miR-21 could be associated with increased podocyte loss. A previous animal study suggested that loss of podocytes
resulted in glomerulosclerosis in mice.\textsuperscript{59} Taken these information together, miR-21 may
plays a protective role in glomerular injury although it is impossible to mention the
causality between miR-21 and glomerular injury in our study.

Few previous studies have focused on the relationship between kidney function and other
miRNAs (miR-17 and miR-150). A wide range of functions in immune activation have
been identified for miR-17.\textsuperscript{60} A case-control study using samples from the Atherosclerosis
Risk in Communities (ARIC) Study demonstrated that miR-17 was downregulated in CKD
cases with hypertension compared with non-CKD cases with hypertension,\textsuperscript{61} indicating
that lower expression of miR-17 in cases induced lower immune activation. Immune
dysfunction among end-stage renal disease patients is well established.\textsuperscript{62} The decline of
kidney function seems to be continual. Immune dysfunction could thus play a role in the
early stages of CKD. Similarly, miR-150 was highly expressed in renal biopsies from
lupus nephritis patients, which might induce increased profibrotic molecules by
downregulating suppressor of cytokine signaling 1, an anti-inflammatory protein.\textsuperscript{32}

However, to the best of our knowledge, the roles of miR-17 and miR-150 on CKD in
general populations have yet to be systemically examined.

Three selected miRNAs examined in this study showed inconsistent associations with
results from previous studies. These discrepancies may be attributable to differences in the
study population (disease severity and presence of comorbidities). We have assumed that
much smaller numbers of participants with renal fibrosis might have been included in our analysis compared with previous studies, because this study was conducted as a part of a health check-up in a community-dwelling population. Indeed, different functions of miR-21 were demonstrated in either normal or injured kidney. Further work is expected to determine the relationships between circulating miRNA expression level and mildly impaired renal function in a population-based study.

A key strength of our study was that we reported significant associations between three circulating miRNAs and CKD in a general population. However, the present study also has some limitations that require discussion. First, the study design of this research was cross-sectional, making the direction of causality impossible to assess. Accordingly, further longitudinal studies with a large sample size could shed light on the causal relationships between circulating miRNAs and CKD in a general population. Second, our study participants were only Japanese and therefore this relationship may not be generalizable to racially different populations with diverse environmental factors, dietary habits, and lifestyles.

Conclusions
The present study suggested that three circulating miRNAs are associated with CKD in the Japanese population. These circulating miRNAs may be a novel biomarker for CKD among general adults.
Acknowledgments

We are grateful for the participation of residents and supports from staffs at the Health Examination Program for Residents of Yakumo, Hokkaido, Japan.

Conflict of interest:

The authors have no conflict of interest to report.
Funding Source:

This study was supported by a Grant-in-Aid for Scientific Research (No. 26293144 and 17K09139) from the Japan Society for the Promotion of Science (JSPS).

Author contributions:

R.F. wrote the manuscript and performed statistical analysis; H.Y., M.Y., O.K., H.I., and K.S. corrected serum samples and clinical information in the health check-up; H.Y., E.M., M.Y., O.K., H.I., and Y.A. performed the experiment; N.H., and K.S. were responsible for the health check-up; K.S. was in charge of data management; K.M., C.H., and S.H. contributed to revise the manuscript critically for important intellectual content. All the authors reviewed the manuscript.
Figure Legends

Figure 1. Scatter plots for the associations of target miRNAs and eGFR. A: miR-17, B: miR-21, and C: miR-150.

miRNA, microRNA; eGFR, estimated glomerular filtration rate.
References

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116: 281–97.

2. Wang F, Chen C, Wang D. Circulating microRNAs in cardiovascular disease: from biomarkers to therapeutic targets. *Front Med* 2014; 8: 404–18.

3. Munetsuna E, Yamada H, Ando Y, Yamazaki M, Tsuboi Y, Kondo M, Mizuno G, Ishikawa H, Sugimoto K, Osakabe K, Ichino N, Ohashi K, Hamajima N, Suzuki K. Association of subcutaneous and visceral fat with circulating microRNAs in a middle-aged Japanese population. *Ann Clin Biochem* 2017; 1: 4563217735124.

4. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. *J Clin Oncol* 2009; 27: 5848–56.

5. Jansson MD, Lund AH. MicroRNA and cancer. *Mol Oncol* 2012; 6: 590–610.

6. Peng Y, Croce CM. The role of MicroRNAs in human cancer. *Signal Transduct Target Ther* 2016; 1: 15004.

7. Price C, Chen J. MicroRNAs in cancer biology and therapy: Current status and perspectives. *Genes Dis* 2014; 1: 53–63.

8. Kong YW, Ferland-Mccollough D, Jackson TJ, Bushell M. microRNA in cancer management. *Lancet Oncol* 2012; 13: e249–58.
9. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. *Cardiovascular Dis* 2008; 79: 562–70.

10. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. *Circ Res* 2007; 101: 1225–36.

11. He Y, Ding Y, Liang B, Lin J, Kim TK, Yu H, Hang H, Wang K. A systematic study of dysregulated microRNA in type 2 diabetes mellitus. *Int J Mol Sci* 2017; 3: 456.

12. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, Sugimoto K, Ohashi K, Teradaira R, Inoue T, Hamajima N, Hashimoto S. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. *Clin Chim Acta* 2013; 424: 99–103.

13. Yamada H, Ohashi K, Suzuki K, Munetsuna E, Ando Y, Yamazaki M, Ishikawa H, Ichino N, Teradaira R, Hashimoto S. Longitudinal study of circulating miR-122 in a rat model of non-alcoholic liver disease. *Clin Chim Acta* 2015; 446: 267–71.

14. Chandrasekaran K, Karolina DS, Sepramaniam S, Armugam A, Wintour EM, Bertram JF, Jeyaseelan K. Role of microRNAs in kidney homeostasis and disease. *Kidney Int* 2012; 81: 617–27.

15. Yamada H, Itoh M, Hiratsuka I, Hashimoto S. Circulating microRNAs in autoimmune thyroid diseases. *Clin Endocrinol* 2014; 81: 276–81.
16. Hiratsuka I, Yamada H, Munetsuna E, Hashimoto S, Itoh M. Circulating microRNAs in Graves’ disease in relation to clinical activity. *Thyroid* 2016; 16: 1431–40.

17. Cortez M, Galin G. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. *Expert Opin Biol Ther* 2009; 9: 703–11.

18. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G. A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. *Urol Oncol* 2010; 28: 656–61.

19. Villarroya-Beltri C, Baixauli F, Gutiérrez-Vázquez C, Sánchez-Madrid F, Mittelbrunn M. Sorting it out: regulation of exosome loading. *Semin Cancer Biol* 2014; 28: 3–13.

20. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNA in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res* 2008; 18: 997–1006.

21. Chin LJ, Slack FJ. A truth serum for cancer—microRNAs have major potential as cancer biomarkers. *Cell Res* 2008; 18: 983–4.
22. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushner M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A. Serum microRNAs are promising novel biomarkers. *PLoS One* 2008; 3: e3148.

23. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q. Circulating microRNAs: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. *Eur Heart J* 2010; 31: 659–66.

24. Japan Nephrology Society. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. *Nihon Jinzo Gakkai Shi* 2012; 54: 1034–191.

25. Dwivedi RS, Herman JG, McCaffrey TA, Raj DS. Beyond genetics: epigenetic code in chronic kidney disease. *Kidney Int* 2011; 79: 23–32.

26. Glowacki F, Savary G, Gnemmi V, Buob D, Van der Hauwaert C, Lo-Guidice JM, Bouyé S, Hazzan M, Pottier N, Perrais M, Aubert S, Cauffiez C. Increased circulating miR-21 levels are associated with kidney fibrosis. *PLoS One* 2013; 8: e58014.

27. Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JY, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. *Nephrol Dial Transplant* 2011; 26: 3794–802.

28. Hennino MF, Buob D, Van der Hauwaert C, Gnemmi V, Jomaa Z, Pottier N, Savary G, Drumez E, Noël C, Cauffiez C, Glowacki F. miR-21-5p renal expression is
associated with fibrosis and renal survival in patients with IgA nephropathy. *Sci Rep* 2016; 6: 272209.

29. Van Craenenbroeck AH, Ledeganck KJ, Van Ackeren K, Jürgens A, Hoymans VY, Fransen E, Adams V, De Winter BY, Verpooten GA, Vrints CJ, Couttenye MM, Van Craenenbroeck EM. Plasma levels of microRNAs in chronic kidney disease: pattern in acute and chronic exercise. *Am J Physiol Heart Circ Physiol* 2015; 309: H2008–16.

30. Lu J, Kwan BC, Lai FM, Tam LS, Li EK, Chow KM, Wang G, Li PK, Szeto CC. Glomerular and tubulointerstitial miR-638, miR-198 and miR-146a expression in lupus nephritis. *Nephrology* 2012; 17: 346–51.

31. Wang G, Kwan BC, Lai FM, Chow KM, Li PK, Szeto CC. Elevated levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy. *Disease Markers* 2011; 30: 171–9.

32. Zhou H, Hasni SA, Perez P, Tandon M, Jang SI, Zheng C, Kopp JB, Austin H 3rd, Balow JE, Alevizos I, Illei GG. miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1. *J Am Soc Nephrol* 2013; 24: 1073–87.

33. Zarjou A, Yang S, Abraham E, Agarwal A, Liu G. Identification of a microRNA signature in renal fibrosis: role of miR-21. *Am J Physiol Renal Physiol* 2011; 301: F793–801.
34. Chen C, Lu C, Qian Y, Li H, Tan Y, Cai L, Weng H. Urinary miR-21 as a potential biomarker of hypertensive kidney injury and fibrosis. *Sci Rep* 2017; 7: 17737.

35. Ichii O, Otsuka S, Sasaki N, Namiki Y, Hashimoto Y, Kon Y. Altered expression of microRNA miR-146a correlates with the development of chronic renal inflammation. *Kidney Int* 2011; 81: 280–92.

36. Ichii O, Horino T. MicroRNAs associated with the development of kidney diseases in humans and animals. *J Toxicol Pathol* 2018; 31: 23–34.

37. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A; Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. *Am J Kidney Dis* 2009; 53: 982–92.

38. Japanese Society of Nephrology. Essential points from Evidence-based Clinical Practice Guidelines for Chronic Kidney Disease 2018. *Clin Exp Nephrol* 2018; ahead of print 1 Dec 2018 DOI: 10.1007/s10157-018-1648-1.

39. Suzuki K, Yamada H, Nagura A, Ohashi K, Ishikawa H, Yamazaki M, Ando Y, Ichino N, Osakabe K, Sugimoto K, Hamajima N, Inoue T. Association of cigarette smoking with serum microRNA expression among middle-aged Japanese adults. *Fujita Medical Journal* 2016; 2: 5.
40. Kloosterman WP, Plasterk RH. The diverse functions of microRNAs in animal development and disease. *Dev Cell* 2006; 11: 441–50.

41. Zhang C. MicroRNomics: a newly emerging approach for disease biology. *Physiol Genomics* 2008; 33: 139–47.

42. Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K, Li Y, Song E, Zheng XL, Xiao H. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2012; 97: 2084–92.

43. Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). *Methods* 2010; 50: 298–301.

44. Zen K, Zang CY. Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. *Med Res Rev* 2012; 32: 326–48.

45. de Ronde MWJ, Ruijter JM, Moerland PD, Creemers EE, Pinto-Sietsma SJ. Study design and qPCR data analysis guideline for reliable circulating miRNA biomarker experiments: a review. *Clin Chem* Epub ahead of print 14 June 2018 DOI: 10.1373/clinchem.2017.285288.

46. Wagner J, Riwanto M, Besler C, Knau A, Fichtlscherer S, Röxe T, Zeiher AM, Landmesser U, Dimmeler S. Characterization of levels and cellular transfer of
circulating lipoprotein-bound microRNAs. Artherioscler Thromb Vasc Biol 2013; 33: 1392–400.

47. Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 2015; 16: 804–15.

48. Fan K, Ritter C, Nghiem P, Blom A, Verhaegen M, Dlugosz A, Odum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC. Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinoma. Clin Cancer Res Epub ahead of print 30 July 2018 DOI: 10.1158/1078-0432.CCR-18-1184.

49. Alhasan AH, Scott AW, Wu JJ, Feng G, Meeks JJ, Thaxton CS, Mirkin CA. Circulating microRNA signature for the diagnosis of very high-risk prostate cancer. Proc Natl Acad Sci U S A 2016; 113: 10655–60.

50. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2007; 71: 159–66.
51. Thum T, Gross C, Fiedler J, Fischer T, Kessler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliantsky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. Micro RNA-21 contributes to myocardial disease by stimulating map kinase signaling in fibroblasts. *Nature* 2008; 456: 980–4.

52. Kölling M, Kaucar T, Schauerte C, Hübner A, Dettling A, Park JK, Busch M, Wulff X, Meier M, Scherf K, Bukosza N, Szénási G, Godó M, Sharma A, Heuser M, Hamar P, Bang C, Haller H, Thum T, Lorenzen JM. Therapeutic miR-21 silencing ameliorates diabetic kidney disease in mice. *Mol Ther* 2017; 25: 165–80.

53. Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, Li J, Tran PT, Kaimal V, Huang X, Chang AN, Li S, Kalra A, Grafals M, Portilla D, MacKenna DA, Orkin SH, Duffield JS. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathway. *Sci Trans Med* 2012; 15: 121ra18.

54. Fan PC, Chen CC, Chen YC, Chang YS, Chu PH. MicroRNAs in acute kidney injury. *Hum Genomics* 2016; 10: 29.

55. Das A, Ganesh K, Khanna S, Sen CK, Roy S. Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation. *J Immunol* 2014; 192: 1120–9.
56. Yang L, Wang B, Zhou Q, Wang Y, Liu X, Liu Z, Zhan Z. MicroRNA-21 prevents excessive inflammation and cardiac dysfunction after myocardial infarction through targeting KBTBD7. *Cell Death Dis* 2018; 9: 769.

57. Hu H, Jiang W, Xi X, Zou C, Ye Z. MicroRNA-21 attenuates renal ischemia reperfusion injury via targeting caspase signaling in mice. *Am J Nephrol* 2014; 40: 215–23.

58. Papagiannakopoulos T, Shapiro A, Kosik KS. MicroRNA-21 targets a network of key tumor-suppressive pathway in glioblastoma cells. *Cancer Res* 2008; 68: 8164–72.

59. Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC. Podocyte depletion causes glomerulosclerosis: Diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. *J Am Soc Nephrol* 2005; 16: 2941–52.

60. Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. *Cell Death Differ* 2013; 20: 1603–14.

61. Nandkumar P, Tin A, Grove ML, Ma J, Boerwinkle E, Coresh J, Chakravarti A. MicroRNAs in the miR-17 and miR-15 families are downregulated in chronic kidney disease with hypertension. *PLoS One* 2017; 12: e0176734.
62. Vanholder R, Ringoir S. Infectious morbidity and detects of phagocytic function in end-stage renal disease: a review. *J Am Soc Nephrol JASN* 1993; 3: 1541–54.

63. Loboda A, Sobczak M, Jozkowicz A, Dulak J. TGF-β1/Smads and miR-21 in renal fibrosis and inflammation. *Mediators Inflamm* 2016; 2016: 8319283.
Table 1. Basic characteristics of participants (N = 513)

|                      | Normal renal function (N = 395) | CKD (N = 118) |
|----------------------|----------------------------------|--------------|
|                      | Mean (Standard deviation)        |              |
| Age (year)           | 63.0 (9.4)                       | 68.5 (8.7)   |
| Body mass index (kg/m²) | 23.5 (3.3)                    | 23.9 (3.2)   |
| Blood glucose (mmol/l) | 5.13 (0.99)                  | 5.18 (0.97)  |
| Systolic blood pressure (mmHg) | 134.4 (19.2)         | 135.4 (18.7) |
| Diastolic blood pressure (mmHg) | 76.4 (12.2)              | 75.8 (12.4)  |
| Triglycerides\(^a\) (mmol/l) | 1.02 [0.73, 1.41]        | 1.06 [0.79, 1.43] |
| HDL-cholesterol (mmol/l) | 1.55 (0.36)                  | 1.51 (0.35)  |
| eGFR\(^b\) (mL/min/1.73m²) | 75.6 (11.4)                | 50.8 (9.2)   |

|                      | Frequency (%) | Frequency (%) |
|----------------------|--------------|--------------|
| Smoking status       |              |              |
| Never                | 200 (50.6%)  | 73 (61.9%)   |
| Ever                 | 133 (33.7%)  | 33 (28.0%)   |
| Current              | 62 (15.7%)   | 12 (10.2%)   |
| Alcohol consumption  |              |              |
| Never                | 219 (55.4%)  | 80 (67.8%)   |
| Ever                 | 18 (4.6%)    | 3 (2.5%)     |
| Current              | 158 (40.0%)  | 35 (29.7%)   |
| Exercise habits       |              |              |
| Almost none          | 241 (61.0%)  | 64 (54.2%)   |
| 1–2h/w               | 89 (22.5%)   | 23 (19.5%)   |
| 3–4h/w               | 32 (8.1%)    | 19 (16.1%)   |
| >5h/w                | 33 (8.4%)    | 12 (10.2%)   |
| Medication for non-communicable diseases\(^c\) | 169 (42.8%) | 83 (70.3%) |

\(^a\) Values are summarized as median [1st quartile, 3rd quartile]

\(^b\) eGFR, estimated glomerular filtration rate

\(^c\) heart disease, diabetes mellitus, hypertension, or dyslipidemia
Table 2. Pearson's correlation coefficients for the associations between microRNAs\textsuperscript{a} and eGFR\textsuperscript{b}

| microRNA | $r$   | $p$-value\textsuperscript{c} |
|----------|-------|-------------------------------|
| let7d    | 0.091 | 0.05                          |
| miR-1    | -0.025| 0.69                          |
| miR-17   | 0.145 | $1.37 \times 10^{-3}$        |
| miR-20a  | 0.027 | 0.55                          |
| miR-21   | 0.203 | $7.04 \times 10^{-6}$        |
| miR-27a  | -0.013| 0.77                          |
| miR-34a  | 0.012 | 0.82                          |
| miR-92   | 0.060 | 0.18                          |
| miR-103a | -0.044| 0.33                          |
| miR-122  | 0.122 | 0.01                          |
| miR-126  | 0.118 | 0.01                          |
| miR-130a | -0.013| 0.78                          |
| miR-133a | -0.021| 0.66                          |
| miR-146  | 0.109 | 0.02                          |
| miR-150  | 0.192 | $1.85 \times 10^{-5}$        |
| miR-192  | 0.047 | 0.30                          |
| miR-195  | 0.045 | 0.32                          |
| miR-197  | 0.08  | 0.08                          |
| miR-199  | -0.013| 0.77                          |
| miR-221  | -0.033| 0.46                          |
| miR-222  | 0.026 | 0.57                          |
| miR-320  | 0.083 | 0.07                          |

\textsuperscript{a} Expression level of microRNAs was used after logarithmic transformation

\textsuperscript{b} eGFR, estimated glomerular filtration rate

\textsuperscript{c} $P$-value less than $2.27 \times 10^{-3}$ was defined as statistically significant
Table 3. Linear regression analysis for the association of circulating microRNAs\textsuperscript{a} with eGFR\textsuperscript{b}

| microRNA | Standardized $\beta$ | $p$-value |
|----------|----------------------|-----------|
| miR-17   | 0.121                | 0.004     |
| miR-21   | 0.134                | 0.002     |
| miR-150  | 0.123                | 0.004     |

Linear regression analyses were performed after adjusting for sex, age, proteinuria, BMI, systolic blood pressure, TG, blood glucose, smoking status, alcohol consumption, exercise habit, and medication for NCDs.

\textsuperscript{a} Expression level of microRNAs was used after logarithmic transformation

\textsuperscript{b} eGFR, estimated glomerular filtration rate
Table 4. Logistic regression analysis for the association of circulating microRNAs\(^a\) with CKD (eGFR\(^b\) < 60 mL/min/1.73m\(^2\))

| miRNA   | miR-17 (N = 484) | miR-21 (N = 484) | miR-150 (N = 493) |
|---------|------------------|------------------|-------------------|
|         | OR\(^c\) (95%CI\(^d\)) | p–value | OR\(^c\) (95%CI\(^d\)) | p–value | OR\(^c\) (95%CI\(^d\)) | p–value |
| Low     | 1.00 | - | 1.00 | - | 1.00 | - |
| Middle  | 0.42 (0.23, 0.73) | 0.003 | 0.71 (0.41, 1.20) | 0.20 | 0.71 (0.41, 1.22) | 0.21 |
| High    | 0.42 (0.24, 0.75) | 0.004 | 0.47 (0.26, 0.85) | 0.01 | 0.49 (0.27, 0.88) | 0.02 |

Logistic regression analyses were performed after adjusting for sex, age, proteinuria, BMI, systolic blood pressure, TG, blood glucose, smoking status, alcohol consumption, exercise habit, and medication for NCDs.

\(^a\) Expression level of microRNAs was used after logarithmic transformation

\(^b\) eGFR, estimated glomerular filtration rate

\(^c\) OR, odds ratio

\(^d\) CI, confidence interval
Figure 1

A

B

C

log(miR-17)

log(miR-21)

log(miR-150)

eGFR (ml/min/1.73m²)

eGFR (ml/min/1.73m²)

eGFR (ml/min/1.73m²)